DexCom Q2 Revenue Hits $1.31B, Raises Full-Year Guidance Across All Key Metrics
DXCM sits 46% above its 52-week low of $54.11.
Summary
DexCom reported Q2 2026 revenue of $1.308 billion, up 13% year-over-year, with GAAP operating income of $318.3 million (24.3% of revenue). The company raised full-year guidance for revenue, gross margin, operating margin, and EBITDA margin, reflecting strong execution and an expanding addressable market.
Key Events · Earnings and Guidance · DXCM
-
Q2 Revenue Grows 13% to $1.31B
Worldwide revenue reached $1.308 billion, driven by 11% U.S. growth and 19% international growth (16% organic). U.S. revenue was $933.4 million, international $375.0 million.
-
Operating Margins Expand 590 bps
GAAP operating income was $318.3 million (24.3% of revenue) vs. $212.6 million (18.4%) a year ago. Non-GAAP operating income was $328.3 million (25.1% of revenue), up from $221.8 million (19.2%).
-
Full-Year Guidance Raised Across the Board
FY2026 revenue guidance raised to $5.18–$5.25 billion (11–13% growth). Non-GAAP gross margin now ~64%, operating margin ~23.5–24%, and adjusted EBITDA margin ~31.5–32%.
-
Strong Balance Sheet with $1.95B in Cash
As of June 30, 2026, Dexcom held $1.95 billion in cash, equivalents, and marketable securities, with its revolving credit facility undrawn, providing significant strategic flexibility.
Analysis · DXCM · Industrial Applications And Services
DexCom delivered a standout quarter with 13% revenue growth and a 590-basis-point expansion in operating margins, both GAAP and non-GAAP. The company raised its full-year outlook for revenue, gross margin, operating margin, and EBITDA margin — a broad-based guidance lift that signals management's confidence in sustained demand and operational leverage. With $1.95 billion in cash and no drawn credit facility, DexCom has ample firepower to fund growth initiatives and the recently announced $1 billion buyback. This report reinforces the bull case that DexCom is successfully expanding beyond its core Type 1 diabetes market into the much larger Type 2 population, supported by the positive CONNECT trial results and the Stelo OTC launch.
At the time of this filing, DXCM was trading at $79.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $28.8B. The 52-week trading range was $54.11 to $89.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.